Very strange how HN elevates news about random drug candidates at very early stages of development.
There is a very active landscape of people developing/validating 'biomarkers' for neurological and psychiatric disorders and developing drugs specifically for those populations with the biomarker present; this news is far from extraordinary.
There is a very active landscape of people developing/validating 'biomarkers' for neurological and psychiatric disorders and developing drugs specifically for those populations with the biomarker present; this news is far from extraordinary.
The real news is when these reach FDA approval.